Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.
Edgardo Santos Castillero, MD, FACP, FASCO
Advertisement
Edgardo S. Santos Castillero, MD, FACP, FASCO, is physician lead at The Oncology Institute, Lung Cancer Center of Excellence; clinical associate professor, Charles E. Schmidt College of Medicine, Florida Atlantic University; and president, Florida Society of Clinical Oncology.
Articles by Edgardo Santos Castillero, MD, FACP, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
3
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
4
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
5